Orphan market exclusivity: ten-year protection for orphan medicines
Orphan market exclusivity gives an authorised orphan medicine ten years in which no similar product may be authorised for the same therapeutic indication.
Article 8 of Regulation (EC) No 141/2000 provides that, once an orphan medicinal product is authorised, the EU and the Member States will not accept another marketing authorisation application, grant an authorisation or accept an extension application for a similar medicinal product in the same therapeutic indication for ten years. A similar product is one with the same principal molecular structural features and the same mechanism of action, defined in Commission Regulation (EC) No 847/2000 as amended in 2018. The period extends to twelve years when a paediatric investigation plan is completed, under Article 37 of Regulation (EC) No 1901/2006.
The exclusivity is separate from data exclusivity and from patents, and it is tied to the orphan indication rather than the product as a whole. It can be cut to six years if, at the end of the fifth year, the product no longer meets the orphan criteria, for instance because the prevalence has risen above five in ten thousand or the product is sufficiently profitable. Article 8(3) allows a second similar product to be authorised despite the exclusivity if the first holder consents, cannot supply sufficient quantities, or if the second product is shown to be safer, more effective or otherwise clinically superior.
What goes wrong: applicants for a similar product discover the exclusivity late in development and must build a clinical superiority case they never planned; holders of several orphan indications on one product assume a single clock, when each indication has its own; and the exclusivity is listed as an asset in valuations without checking whether a Member State has started the fifth-year review. Companies sometimes also forget that a generic of an orphan product is blocked by the exclusivity even after data and market protection have run out, and that the block applies in every Member State, not only where the orphan product is marketed.
Under the new pharma package (not yet in force), the standard period becomes nine years, rising to eleven for orphan medicines addressing a high unmet medical need and falling to four for products authorised on bibliographic data, under Article 73 of the agreed regulation text; see exclusivity changes.
Used in
Portfolio and planning teams record orphan exclusivity periods alongside patents and data protection in the loss-of-exclusivity workflow.
Related terms
- Orphan designation: status for medicines for rare conditionsOrphan designation is EU status for a medicine for a rare condition, bringing fee reductions, protocol assistance and market exclusivity once authorised.
- Data exclusivity: regulatory data protectionData exclusivity is the eight years after a reference product's first EU authorisation in which generics cannot rely on its preclinical and clinical data.
- Paediatric extension: six-month SPC extension for a completed PIPThe paediatric extension adds six months to a supplementary protection certificate as a reward for completing an agreed paediatric investigation plan.
- Market protection: period in which generics cannot be marketedMarket protection is the period after data exclusivity ends during which a generic or biosimilar can be authorised but not placed on the market.
- PIP: paediatric investigation planA paediatric investigation plan (PIP) is the agreed programme of studies in children a new medicine must complete, waive or defer before EU authorisation.
Last updated